MedPath
HSA Product

THYROCORD 25 TABLET 25 MCG

Product approved by Health Sciences Authority (SG)

Basic Information

THYROCORD 25 TABLET 25 MCG

TABLET

Regulatory Information

SIN16701P

February 21, 2023

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XH03AA01

Company Information

ACCORD HEALTHCARE PRIVATE LIMITED

ACCORD HEALTHCARE PRIVATE LIMITED

Active Ingredients

Levothyroxine Sodium

Strength: 0.025 mg

Detailed Information

Contraindications

**CONTRAINDICATIONS** Thyrocord must not be used in patients with: - hypersensitivity to any of the excipients of the product (see 'Composition' – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) - untreated adrenal insufficiency - untreated pituitary insufficiency - hyperthyroidism or untreated thyrotoxicosis, including untreated subclinical (suppressed serum TSH level with normal T3 and T4 levels) hyperthyroidism. Treatment with levothyroxine must not be initiated in patients with acute myocardial infarction, acute myocarditis, or acute pancarditis. Combination therapy of Thyrocord and an antithyroid agent for hyperthyroidism is not indicated during pregnancy.

Indication Information

**INDICATIONS** Hypothyroidism.

© Copyright 2025. All Rights Reserved by MedPath